Skip to main content
. 2018 Sep 25;2(10):1247–1258. doi: 10.1002/hep4.1240

Figure 5.

Figure 5

Serum CEACAM1 levels and CD107a expression on NK cells in patients with CHC. (A) Serum CEACAM1 levels were measured in healthy subjects, patients with CHC, patients who achieved an SVR, patients with CHB, and patients with NASH using an ELISA. (B) In patients with CHC, serum CEACAM1 levels correlated significantly with serum HCV‐RNA loads. (C) We examined serum CEACAM1 levels using an ELISA and CD107a expression on NK cells cocultured with K562 cells by flow cytometry. In 23 patients with CHC, serum CEACAM1 levels were inversely correlated with CD 107a expression on NK cells. (D) We measured CD107a expression on naïve NK cells in 15 of 23 patients with CHC before and after treatment by flow cytometry. (E) Serum CEACAM1 levels in all 15 patients shown in (D) were analyzed before and after treatment using an ELISA. (F) Using qRT‐PCR, we examined levels of CEACAM1 mRNA in 11 liver tissues obtained from uninfected patients through a hepatectomy and from 46 liver tissues obtained from patients with CHC through a liver biopsy.